两种超低容量肠道准备方案在筛查中的腺瘤检出率与耐受性:一项非劣效性随机对照试验
该研究在iFOBT阳性、50至69岁接受晨间结肠镜检查的筛查人群中,比较1L聚乙二醇加抗坏血酸(1L-PEGA)与匹可硫酸钠加枸橼酸镁(SPMC)分次给药的腺瘤检出率(ADR)。共纳入1002例,每组501例。SPMC组ADR为56.5%,1L-PEGA组为53.7%,相对风险0.95(95%CI 0.85-1.06),SPMC在ADR方面对1L-PEGA非劣效(差值2.8%,双侧95%置信下限-3.4)。1L-PEGA肠道准备质量更优(96.2% vs 89.2%,P<.001),SPMC安全性和耐受性更高(非严重治疗中出现的不良事件更少)。
要点
- 在iFOBT阳性筛查人群中,SPMC在腺瘤检出率方面对1L-PEGA非劣效。
- 1L-PEGA肠道准备质量优于SPMC(96.2% vs 89.2%,P<.001)。
- SPMC的非严重治疗中出现的不良事件更少,安全性和耐受性更高。
核心结论
- SPMC在腺瘤检出率方面对1L-PEGA非劣效。
- 尽管1L-PEGA肠道准备质量更优,SPMC的安全、耐受性和总体满意度更高。
研究设计与样本
- 比较性、平行、随机、非劣效性、低干预临床试验。
- 目标人群为50至69岁、iFOBT阳性、预约晨间结肠镜检查的结直肠癌筛查项目个体。
- 共纳入1002例受试者,随机分配至1L-PEGA组或SPMC组,每组501例。
- 主要结局为腺瘤检出率,次要结局为肠道准备质量、安全性、耐受性和满意度。
主要发现
- 汇总腺瘤检出率:SPMC组56.5%(95%CI 52.1-60.8),1L-PEGA组53.7%(95%CI 49.3-58.0),相对风险0.95(95%CI 0.85-1.06)。
- SPMC对1L-PEGA的腺瘤检出率差值为2.8%,双侧95%置信下限为-3.4。
- 两组间平均病灶数无论大小和位置均无显著差异。
- 肠道准备质量1L-PEGA优于SPMC(96.2% vs 89.2%,P<.001)。
- SPMC的非严重治疗中出现的不良事件更少,安全性和耐受性显著更高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The adenoma detection rate (ADR), recognized as a surrogate marker for colorectal cancer (CRC) incidence and mortality reduction, is closely linked to the efficacy of bowel cleansing. However, there is a dearth of evidence examining the impact on ADR when using 2 distinct very-low-dose bowel cleansing products. This study sought to compare ADR in an immunochemical fecal occult blood test (iFOBT)-based organized screening program by using 1 L of polyethylene glycol plus ascorbate (1L-PEGA) versus sodium picosulfate with magnesium citrate (SPMC), both administered in a split-dose regimen. METHODS: We conducted a comparative, parallel, randomized, noninferiority, and low-intervention clinical trial targeting individuals from a population CRC screening program aged 50 to 69 years with a positive iFOBT result scheduled for a workup colonoscopy in the morning. Participants were randomized to either 1L-PEGA or SPMC for bowel cleansing. The main outcome was ADR, whereas secondary outcomes were bowel preparation quality, safety, tolerability, and satisfaction. RESULTS: A total of 1002 subjects, 501 were included in each group. There were no differences between groups with respect to pooled ADR (SPMC, 56.5% [95% CI, 52.1-60.8]; 1L-PEGA, 53.7% [95% CI, 49.3-58.0]; relative risk, .95 [95% CI, .85-1.06]); therefore, SPMC demonstrated noninferiority in ADR compared with 1L-PEGA (difference, 2.8%; 2-sided 95% lower confidence limit, -3.4). In addition, there were no significant differences in mean lesions regardless of size and location between arms. Bowel preparation favored 1L-PEGA (96.2% vs 89.2%, P < .001), whereas SPMC exhibited significantly higher safety and tolerability, as shown by fewer nonserious treatment-emergent adverse events. CONCLUSIONS: SPMC emerged as a noninferior laxative compared with 1L-PEGA concerning ADR. Despite the superior bowel preparation quality associated with 1L-PEGA, the safety, tolerability, and overall satisfaction of participants were higher with SPMC. (Clinical trial registration number: EudraCT: 2019-003186-18.).
引用
- Serradesanferm A, Torá-Rocamora I, Pozo À, et al. Adenoma detection rate and tolerability of 2 ultra-low-volume bowel preparations in screening: a noninferiority randomized controlled trial. Gastrointest Endosc. 2024. PMID: 39069266. doi:10.1016/j.gie.2024.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。